1260590-51-9 Usage
Description
N-Methyl-N-((3R,4R)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine dihydrochloride is a chemical compound that serves as a reagent in the synthesis of Tofacitinib (CP-690,550), a Janus tyrosine kinase (JAK3) specific inhibitor. It is also utilized in the identification of related substances in the degradation products of tofacitinib citrate through the LC-MS technique, which is crucial for process monitoring and quality assurance in pharmaceutical manufacturing.
Uses
Used in Pharmaceutical Industry:
N-Methyl-N-((3R,4R)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine dihydrochloride is used as a reagent for the synthesis of Tofacitinib (CP-690,550), a Janus tyrosine kinase (JAK3) specific inhibitor, which is an important drug for treating various inflammatory and autoimmune diseases.
Used in Quality Assurance and Process Monitoring:
N-Methyl-N-((3R,4R)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine dihydrochloride is used as a substance in the identification of related substances in the degradation products of tofacitinib citrate. This application is crucial for process monitoring and quality assurance in the pharmaceutical industry, as it helps ensure the safety, efficacy, and purity of the final drug product by employing the LC-MS technique.
Synthesis
Add TFTB-1, sodium hydroxide, ethanol and water to a 20L reaction flask, heat to 85 ° C, and keep the reaction for 3 hours. At the end of the reaction, vacuum distillation at 80-90 ° C until no liquid flows out. Add purified water and continue stirring. The mixture was cooled to room temperature, extracted with dichloromethane, and the aqueous layer was extracted with methylene chloride. The organic layer was combined, and the organic layer was washed with purified water. Filtration, evaporation of the filtrate, addition of acetone, reflux for 30 min, cooling to 20 ° C, filtration, filter cake into a dry box, drying at 60 ° C ± 5 ° C for 4 h, to obtain a white solid, that is, TFTB-2, yield 86%.
Check Digit Verification of cas no
The CAS Registry Mumber 1260590-51-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,0,5,9 and 0 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1260590-51:
(9*1)+(8*2)+(7*6)+(6*0)+(5*5)+(4*9)+(3*0)+(2*5)+(1*1)=139
139 % 10 = 9
So 1260590-51-9 is a valid CAS Registry Number.
1260590-51-9Relevant articles and documents
Preparation method of tofacitinib intermediate
-
, (2021/04/21)
The invention belongs to the field of pharmaceutical chemicals, and relates to a preparation method of a tofacitinib intermediate. According to the preparation method, in the process of preparing a compound shown as a formula II from a compound shown as a
Tofacitinib citrate intermediate as well as preparation method and application thereof
-
Paragraph 0046-0048; 0052-0054; 0057-0059, (2020/12/10)
The invention belongs to the technical field of medicinal chemistry, and particularly relates to a tofacitinib citrate intermediate as well as a preparation method and an application thereof. Whereinthe tofacitinib citrate intermediate is N-methyl-N-((3R, 4R)-4-methylpiperidine-3-yl)-7H-pyrrolo [2, 3-D] pyrimidine-4-amine dihydrochloride monohydrate. The preparation method comprises the followingsteps: adding N-methyl-N-((3R, 4R)-1-benzyl-4-methylpiperidine-3-yl)-N-methyl-7H-pyrrolo [2, 3-d] pyrimidine-4-amine into water and an organic solvent, then adding hydrochloric acid and palladium hydroxide carbon, introducing hydrogen to react, and filtering out the palladium hydroxide carbon; cooling to room temperature, dropwise adding an organic solvent, crystallizing, carrying out suction filtration, and drying to obtain the tofacitinib citrate intermediate. The method greatly improves the utilization rate of raw materials, reduces the production cost, and improves the product quality.
Preparation method for tofacitinib citrate
-
Paragraph 0045-0046, (2019/06/07)
The invention relates to the field of medicinal chemistry, and provides a preparation method for tofacitinib. ((3R,4R)-1-benzyl-4-methyl-piperidine-3-radical)-methyl-(7H-pyrrolo [2, 3-D] pyrimidine-4-radical)-amine is taken as a starting material, after the hydrogenation debenzylation reaction and amidation, tofacitinib is prepared, and after the tofacitinib and citric acid are salified, the tofacitinib citrate is obtained. According to the developed technology, the product quality is quite high, the purity is 99.9% or above, the content of any individual impurity is less than 0.1%, and the quality standard of tofacitinib citrate medicine as a registered active pharmaceutical ingredient is met. The hydrogenation reaction utilizes an aqueous hydrochloric acid solution as a solvent, and thehydrogenation reaction is quite safe, green and environmentally friendly.
